Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093963 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression
A Phase 3 study, sponsored by Lindner Center of HOPE.
- Terminated
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT01093963 is a Phase 3 study that was terminated before completion, run by Lindner Center of HOPE. The registered enrollment target is 25 participants.
The verdict
NCT01093963, a Phase 3 study, was terminated before completion, sponsored by Lindner Center of HOPE.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
The specific aim of this study is to evaluate the efficacy and tolerability of a stimulant (lisdexamfetamine) in the adjunctive treatment of bipolar disorder.
Interventions
- DRUG Placebo
- DRUG Lisdexamfetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093963
The ClinicalTrials.gov registry entry for NCT01093963 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01093963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01093963 about?
NCT01093963 is a clinical study titled "Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression". The specific aim of this study is to evaluate the efficacy and tolerability of a stimulant (lisdexamfetamine) in the adjunctive treatment of bipolar disorder.
What is the current status of trial NCT01093963?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2010-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01093963?
The interventions under investigation include: Placebo (DRUG), Lisdexamfetamine (DRUG).
Who is sponsoring clinical trial NCT01093963?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.